Spots Global Cancer Trial Database for parp inhibitor
Every month we try and update this database with for parp inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | NCT02042378 | Pancreatic Canc... Pancreatic Duct... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | NCT04703920 | Metastatic Brea... Metastatic Cast... Metastatic Ovar... | Talazoparib Belinostat | 18 Years - | University of Michigan Rogel Cancer Center | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | NCT01063517 | Gastric Cancer | olaparib paclitaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | NCT04503265 | Advanced Malign... Breast Cancer Ovarian Cancer Homologous Reco... Prostate Cancer Pancreatic Canc... | AMXI-5001:Dose ... AMXI-5001:Dose ... | 18 Years - | AtlasMedx, Incorporated | |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | NCT03954366 | Neoplasms | Rucaparib Rosuvastatin Oral Contracept... | 18 Years - | pharmaand GmbH | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) | NCT03167619 | Triple Negative... | Olaparib Oral P... Olaparib Oral P... | 21 Years - | Duke University | |
| M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501) | NCT06421935 | Advanced Solid ... | M9466 Tuvusertib | 18 Years - | EMD Serono | |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | NCT02033551 | Breast Cancer Ovarian Cancer Colon Cancer Lung Cancer Gastric Cancer Solid Tumors | Veliparib Carboplatin Paclitaxel FOLFIRI | 18 Years - 99 Years | AbbVie | |
| Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours | NCT00710268 | Neoplasm Metast... | AZD2281 Bevacizumab | 18 Years - | AstraZeneca | |
| Pembrolizumab Plus Olaparib in LA-HNSCC | NCT05366166 | Squamous Cell C... | Pembrolizumab Olaparib Cisplatin IMRT (intensity... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | NCT01968213 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Rucaparib Placebo | 18 Years - | pharmaand GmbH | |
| CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | NCT05942300 | Recurrent Ovari... | CPI-0209 carboplatin | 18 Years - | University of Pittsburgh | |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | NCT02769962 | Urothelial Carc... Urothelial Canc... Lung Neoplasms Small Cell Lung... Prostate Cancer | EP0057 olaparib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | NCT00994071 | Medulloblastoma Pontine Glioma Ependymoma Astrocytoma PNET | Temozolomide ABT-888 | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation | NCT01472783 | Recurrent, Epit... | Veliparib | 18 Years - | Vejle Hospital | |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT03397394 | Bladder Cancer Urothelial Carc... Metastatic Urot... Renal Pelvis Ca... Ureter Carcinom... Urinary Bladder... Urethra Carcino... Muscle Invasive... | Rucaparib | 18 Years - | pharmaand GmbH | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT02412371 | Non-small Cell ... | Paclitaxel Placebo for Vel... Carboplatin Veliparib Radiotherapy | 18 Years - | AbbVie | |
| The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | NCT03551171 | Ovarian Cancer | ZL-2306 (nirapa... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems | NCT01419548 | Neoplasms | ABT-888 Carboplatin Paclitaxel | 18 Years - 110 Years | National Institutes of Health Clinical Center (CC) | |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | NCT02657889 | Neoplasms Triple Negative... Ovarian Cancer Breast Cancer Metastatic Brea... Advanced Breast... Stage IV Breast... Fallopian Tube ... Peritoneal Canc... | niraparib pembrolizumab | 18 Years - | Tesaro, Inc. | |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy | NCT05990192 | Ovarian Cancer ... | Niraparib oral ... SBRT | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | NCT03404960 | Pancreatic Aden... | Niraparib + Niv... Niraparib + Ipi... | 18 Years - | University of Pennsylvania | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy | NCT05990192 | Ovarian Cancer ... | Niraparib oral ... SBRT | 18 Years - | Institute of Cancer Research, United Kingdom | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer | NCT04724031 | Ovarian Cancer | PARP inhibitor | 18 Years - 80 Years | Hellenic Cooperative Oncology Group | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | NCT03672773 | Recurrent Exten... Refractory Exte... | Talazoparib Temozolomide | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) | NCT01945775 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib Physician's-Cho... | 18 Years - | Pfizer | |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | NCT03075462 | Ovarian Cancer Triple Negative... | Fluzoparib Apatinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems | NCT01419548 | Neoplasms | ABT-888 Carboplatin Paclitaxel | 18 Years - 110 Years | National Institutes of Health Clinical Center (CC) | |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | NCT02854436 | Prostatic Neopl... | Niraparib | 18 Years - | Janssen Research & Development, LLC | |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | NCT01905592 | Neoplasms, Brea... Carcinoma of Br... Human Epidermal... BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Neoplas... | niraparib Physician's cho... | 18 Years - | Tesaro, Inc. | |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | NCT02305758 | Untreated Metas... | Veliparib Placebo Modified FOLFIR... FOLFIRI Bevacizumab Fluorouracil in... | 18 Years - 99 Years | AbbVie | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer | NCT01445522 | Neoplasms Lymphoma | ABT-888 Cyclophosphamid... | 18 Years - 110 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) | NCT01945775 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib Physician's-Cho... | 18 Years - | Pfizer | |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | NCT04644068 | Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer Additional Indi... Non-small Cell ... Colorectal Canc... Bladder Cancer Gastric Cancer Biliary Cancer Cervical Cancer Endometrial Can... Small Cell Lung... | AZD5305 Paclitaxel Carboplatin T- Dxd Dato-DXd Camizestrant | 18 Years - 130 Years | AstraZeneca | |
| Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | NCT06380660 | Solid Tumor, Ad... BRCA1 Mutation BRCA2 Mutation Ovarian Cancer Breast Cancer Prostate Cancer | ACE-86225106 ta... | 18 Years - | Acerand Therapeutics Limited | |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | NCT05494580 | Ovarian Cancer Ovarian Carcino... Platinum-resist... Fallopian Tube ... Primary Periton... | Pamiparib Surufatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib | NCT02986100 | Solid Tumor | C-14 labeled Ru... Rucaparib | 18 Years - | pharmaand GmbH | |
| Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | NCT04910022 | Glioblastoma Diffuse Glioma | NMS-03305293 Temozolomide | 18 Years - | Nerviano Medical Sciences | |
| Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | NCT04716686 | Endometrial Car... Serous Carcinom... | Niraparib | 18 Years - | Shandong University | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer | NCT04582552 | Ovarian Cancer Clinical Marker PARP Inhibitor | PARP inhibitors | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | NCT01874353 | Platinum Sensit... BRCA Mutated Relapsed Ovaria... Following Compl... | Olaparib 300mg ... Placebo to matc... | 18 Years - 130 Years | AstraZeneca | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | NCT05551208 | Ovarian Cancer | fluzopanib and ... | 18 Years - 75 Years | Chongqing University Cancer Hospital | |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | NCT02305758 | Untreated Metas... | Veliparib Placebo Modified FOLFIR... FOLFIRI Bevacizumab Fluorouracil in... | 18 Years - 99 Years | AbbVie | |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | NCT04672460 | Advanced Solid ... Solid Tumors Ovarian Cancer Breast Cancer Prostate Cancer NSCLC Pancreatic Canc... Colorectal Canc... | TALZENNA capsul... Talazoparib sof... Talazoparib sof... | 18 Years - 70 Years | Pfizer | |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers | NCT00678132 | Neoplasms | AZD 2281 Cisplatin Gemcitabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | NCT03954366 | Neoplasms | Rucaparib Rosuvastatin Oral Contracept... | 18 Years - | pharmaand GmbH | |
| PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) | NCT06074692 | Sarcoma Sarcoma,Soft Ti... Sarcoma of Bone | Camrelizumab an... | 10 Years - 70 Years | Ruijin Hospital | |
| A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | NCT03207347 | Mesothelioma Uveal Melanoma Renal Cell Carc... Cholangiocarcin... | Niraparib | 18 Years - 80 Years | University of Florida | |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501) | NCT06421935 | Advanced Solid ... | M9466 Tuvusertib | 18 Years - | EMD Serono | |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | NCT01482715 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Advanced Solid ... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd | NCT04740190 | Recurrent Gliom... Recurrent Gliob... Poly ADP Ribose... PTEN Gene Inact... IDH Mutation | Talazoparib | 18 Years - | The University of Hong Kong | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | NCT05406999 | Neoadjuvant The... High Risk Prost... Locally Advance... Intense Endocri... | ADT Abiraterone Ace... Prednisolone ta... Enzalutamide Apalutamide Darotamide Rezvilutamide PARP inhibitor Robot-assisted ... | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| Phase II ABT-888 With Cyclophosphamide | NCT01306032 | Ovarian Cancer Primary Periton... Serous Carcinom... Triple-Negative... Fallopian Tube ... | ABT-888 Cyclophosphamid... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | NCT01074970 | Breast Cancer | Cisplatin Rucaparib Cisplatin | 18 Years - | Hoosier Cancer Research Network | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | NCT05200260 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Primary debulki... Neoadjuvant che... PARP inhibitor | 18 Years - | Shanghai Gynecologic Oncology Group | |
| A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | NCT00526617 | Non-hematologic... Metastatic Mela... Breast Cancer Ovarian Cancer Primary Periton... Fallopian Tube ... Hepatocellular ... | ABT-888 Temozolomide | 18 Years - | AbbVie | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | NCT03639935 | Biliary Tract C... | Rucaparib Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
